Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Sci ; 195: 106661, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38052257

ABSTRACT

Temozolomide (TMZ) a DNA alkylating agent, is the standard-of-care for brain tumors, such as glioblastoma multiforme (GBM). Although the physicochemical and pharmacokinetic properties of TMZ, such as chemical stability and the ability to cross the blood-brain barrier (BBB), have been questioned in the past, the acquired chemoresistance has been the main limiting factor of long-term clinical use of TMZ. In the present study, an L-type amino acid transporter 1 (LAT1)-utilizing prodrug of TMZ (TMZ-AA, 6) was prepared and studied for its cellular accumulation and cytotoxic properties in human squamous cell carcinoma, UT-SCC-28 and UT-SCC-42B cells, and TMZ-sensitive human glioma, U-87MG cells that expressed functional LAT1. TMZ-AA 6 accumulated more effectively than TMZ itself into those cancer cells that expressed LAT1 (UT-SCC-42B). However, this did not correlate with decreased viability of treated cells. Indeed, TMZ-AA 6, similarly to TMZ itself, required adjuvant inhibitor(s) of DNA-repair systems, O6-methylguanine-DNA methyl transferase (MGMT) and base excision repair (BER), as well as active DNA mismatch repair (MMR), for maximal growth inhibition. The present study shows that improving the delivery of this widely-used methylating agent is not the main barrier to improved chemotherapy, although utilizing a specific transporter overexpressed at the BBB or glioma cells can have targeting advantages. To obtain a more effective anticancer prodrug, the compound design focus should shift to altering the major DNA alkylation site or inhibiting DNA repair systems.


Subject(s)
Brain Neoplasms , Glioblastoma , Glioma , Prodrugs , Humans , Temozolomide/pharmacology , Temozolomide/therapeutic use , Antineoplastic Agents, Alkylating/pharmacology , Dacarbazine/pharmacology , Drug Resistance, Neoplasm , DNA Repair , Glioblastoma/drug therapy , Glioma/drug therapy , Brain Neoplasms/drug therapy , DNA , Prodrugs/pharmacology , Prodrugs/therapeutic use , Cell Line, Tumor
2.
Molecules ; 27(19)2022 Sep 26.
Article in English | MEDLINE | ID: mdl-36234897

ABSTRACT

Cydonia oblonga is a medicinal plant that is used to treat a number of health complications in traditional medication systems. The objective of this study was to evaluate the phytochemical composition, and antibacterial, antioxidant, and ant-diabetic potentials of methanolic extracts of Cydonia oblonga bark. The Cydonia oblonga bark extraction was fractionated through HPLC and seven purified fractions labeled as F1, F2, F3, F4, F5, F6, and F7 were obtained. The HPLC-UV analysis of methanolic extract showed the presence of a number of possible compounds. The GC-MS and HPLC analysis confirmed the presence of the following bioactive compounds in the crude extract and purified fractions: malic acid, mandelic acid, quercetin, caffeic acid, catechin hydrate, as morin (HPLC analysis), BIS-(2-ethylhexyl)phthalate and diisooctyl phthalate (F1), carbamide (F2, used as fertilizer), octasiloxane and dimethylsiloxanecyclictrimer (F3), silicic acid and cyclotrisiloxane (F4), 6-AH-cAMP, 4H-cyclopropa[5',6']benz[1',2',7,8]azule, and 4-(4-chlorophenyl)-3-morpholinepyrol-2-yl)-butenedioic acid (F5), isopropyamine (F6), and 1-propylhydrazine (F7). The extract and purified fractions were then tested for biological activities. All the purified fractions and methanolic extract showed effective antibacterial activity; however, the highest activity was recorded for methanolic extract against Staphylococcus aureus and Streptococcus pneumonia. Antioxidant evaluation of methanolic extract and purified fractions against DPPH showed strong % inhibition of the synthetic free radical. The methanolic extract exhibited 87.41 ± 0.54% inhibition whereas fractions showed: F1, 85.45 ± 0.85; F2, 65.78 ± 0.68; F3, 58.61 ± 0.58; F4, 80.76 ± 0.59; F5, 571.29 ± 0.49; F6, 85.28 ± 0.94; and F7, 48.45 ± 0.62% inhibition. Ascorbic acid (standard) was used as a control with 94.88 ± 0.56% inhibition at a maximum concentration of 1000 µg/mL. The α-glucosidase inhibition assay of methanolic extract and purified fractions at a maximum concentration of 1000 µg/mL showed activities as: methanolic extract, 78.21 ± 0.67; F1, 55.01 ± 0.29; F2, 56.10 ± 0.24; F3, 62.44 ± 1.03; F4, 70.52 ± 0.15; F5, 62.18 ± 0.92; F6, 72.68 ± 0.2; and F7, 57.33 ± 0.05% inhibition. α-Amylase % inhibition of methanolic extract and purified fractions were noted as: methanolic extract, 77.98 ± 0.57; F1, 79.72 ± 0.02; F2, 79.72 ± 0.02; F3, 82.16 ± 0.48; F4, 77.37 ± 0.28; F5, 72.14 ± 0.30; F6, 74.24 ± 0.29; and F7, 56.58 ± 0.10 at the highest concentration of 1000 µg/mL. Acarbose (standard) showed 87.65 ± 0.71% inhibition of α-glucosidase and 85.99 ± 0.44% inhibition of α-amylase at the highest concentration of 1000 µg/mL. It was found that all biological activities of methanolic extract and purified fractions might be attributed to the fact that they are rich sources of phenolic and flavonoids along with other bioactive compounds. The total phenolic and flavonoid contents of methanolic extract were recorded higher as compared to purified fractions (TPC = 70% and TFC = 69%). Amongst the purified fractions, fraction 6 exhibited the highest TPC value (64%), and purified fraction 1 exhibited the highest value of TFC (58%). Recent research demonstrated that Cydonia oblonga may be considered an antibacterial medicinal plant. The result of the present study revealed that it might be utilized for the isolation of bioactive phytochemicals that can lead to new opportunities in the discovery of new antibiotics.


Subject(s)
Catechin , Rosaceae , Acarbose/analysis , Anti-Bacterial Agents/analysis , Anti-Bacterial Agents/pharmacology , Antioxidants/chemistry , Ascorbic Acid/analysis , Catechin/analysis , Fertilizers/analysis , Flavonoids/pharmacology , Free Radicals/analysis , Hypoglycemic Agents/analysis , Hypoglycemic Agents/pharmacology , Phenols/analysis , Phytochemicals/chemistry , Plant Bark/chemistry , Plant Extracts/chemistry , Quercetin/analysis , Quercetin/pharmacology , Silicic Acid , Urea/analysis , alpha-Amylases , alpha-Glucosidases
3.
Mikrochim Acta ; 186(9): 595, 2019 08 02.
Article in English | MEDLINE | ID: mdl-31375925

ABSTRACT

A cyclic voltammetric method is described for the determination of nitrite by using a multiwalled carbon nanotube paste electrode (MWCNT) that was modified with chitosan-functionalized silver nanoparticles (Chit-AgNPs). The AgNPs were prepared by one step procedure using chitosan as stabilizing agent. The resulting modified AgNPs were drop-coated onto the electrode. By combining the advantages of chitosan, AgNPs (in the form of Chit-AgNPs) and MWCNT, the assay exhibits a remarkable improvement in the cyclic voltammetric response towards the oxidation of nitrite at a typical peak potential of 0.81 V (vs. SCE) in buffer of pH 4.0. The accumulation of nitrite on the electrode also was achieved, and this further enhances the analytical sensitivity. Under optimized conditions, the oxidation peak current increases linearly in the 100 nM to 50 µM nitrite concentration range, and the detection limit is 30 nM. The method has high selectivity for nitrite even in the presence of other potentially interfering ions. Graphical abstract Schematic illustration of the prepared chitosan functionalized silver nanoparticles (transmission electron microscope image) and modification of multi-walled carbon nanotube paste electrode with chitosan functionalized silver nanoparticles for the electrochemical oxidation of nitrite to nitrate.

SELECTION OF CITATIONS
SEARCH DETAIL
...